Streetbeat News

Price Targets

HRMY

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:59 pm

VRTX

Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a $365 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:58 pm

REGN

Cantor Fitzgerald analyst Alethia Young reiterated a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained an $815 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:57 pm

ALNY

Cantor Fitzgerald analyst Olivia Brayer reiterated a Neutral rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $200 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:56 pm

JOBY

Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on Joby Aviation (NYSE:JOBY) and maintained a $9 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:56 pm

EVEX

Cantor Fitzgerald analyst Andres Sheppard reiterated a Neutral rating on Eve Holding (NYSE:EVEX) and maintained a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:55 pm

ACHR

Cantor Fitzgerald analyst Andres Sheppard reiterated an Overweight rating on Archer Aviation (NYSE:ACHR) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:54 pm

XAIR

Beyond Air reported worse-than-expected Q4 EPS results, causing its shares to trade lower. Oppenheimer maintained an Outperform rating but lowered its price target from $16 to $10.

Portfolio Pulse from Benzinga Newsdesk

June 23, 2023 | 3:53 pm

PFE

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on Pfizer (NYSE:PFE) and maintained a $75 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:53 pm

SEEL

Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Seelos Therapeutics (NASDAQ:SEEL) and maintained a $2 price target.

Portfolio Pulse from richadhand@benzinga.com

June 23, 2023 | 3:52 pm